KRONOX Lab Sciences Limited has announced a Board of Directors meeting scheduled for February 14, 2026, to review and approve the company's quarterly financial performance. The meeting will focus on considering the unaudited standalone financial results for both the quarter and nine months ended December 31, 2025.

Board Meeting Details

The company has formally communicated the board meeting schedule in compliance with regulatory requirements. The meeting agenda and key details are outlined below:

Regulatory Compliance and Trading Window

KRONOX Lab Sciences Limited has implemented the necessary regulatory measures in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has established a trading window closure as part of its compliance framework.

The trading restrictions are comprehensive and affect multiple stakeholder categories:

• Effective Date: January 01, 2026
• Applicable Parties: Directors, Officers, and designated employees
• Duration: Until 48 hours after declaration of financial results
• Scope: Trading in company securities

Financial Results Timeline

The upcoming board meeting will address the company's financial performance for a significant reporting period. The unaudited standalone financial results will cover the quarter ended December 31, 2025, as well as the cumulative nine-month performance for the same period.

Corporate Governance

The announcement was formally communicated by Nikhil Goswami, Company Secretary with Membership No. A68272, ensuring proper corporate governance protocols are followed. The communication was digitally signed and dated February 09, 2026, demonstrating the company's commitment to transparent and timely disclosure practices.

The scheduled board meeting represents a routine but important corporate milestone, allowing stakeholders to assess the company's financial performance and strategic direction for the reporting period.

Kronox Lab Sciences , a manufacturer of high-purity specialty fine chemicals, has announced its financial results for the quarter and half-year ended September 30, 2025, showing strong performance in both revenue and profit.

Financial Highlights

The company reported significant figures for both the quarter and half-year periods. Here's a breakdown of the key financial metrics:

Revenue and Profit Analysis

Kronox Lab Sciences' revenue from operations for the quarter reached ₹2,553.32 lakhs, while the half-year figure stood at ₹4,981.97 lakhs. This performance indicates strong demand for the company's high-purity specialty fine chemicals.

The company's profit after tax for the quarter was ₹1,129.96 lakhs, with the half-year figure reaching ₹2,546.70 lakhs. These profit figures suggest that Kronox Lab Sciences has maintained operational efficiency and cost management.

Corporate Developments

• The Board of Directors approved the standalone unaudited financial results during their meeting.
• Kronox Lab Sciences operates in the manufacturing of high purity specialty fine chemicals as its single reportable segment.
• The company had completed its IPO, which was a 100% Offer for Sale (OFS).
• A final dividend of 5% for FY24-25 was declared and paid out in September 2025.

Audit and Review

The financial results were reviewed by statutory auditors and recommended by the audit committee, ensuring compliance with regulatory requirements and maintaining transparency in financial reporting.

Conclusion

Kronox Lab Sciences' financial results for the quarter and half-year ended September 30, 2025, demonstrate strong performance in both revenue generation and profitability. The company's profit levels suggest effective cost management and operational efficiency. As Kronox Lab Sciences continues to operate in the specialty chemicals market, investors and stakeholders will be watching closely to see how the company performs in the high-purity specialty fine chemicals sector.